Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-12-19

Clinical Trial Update: A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis [Phase 2]

View source ↗

Summary

This entry summarizes the results of a Phase 2 safety and effectiveness study of CNTO 1275 in adults with moderate to severe plaque-type psoriasis. The trial st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CNTO 1275 (ustekinumab)

Snippet

Sponsor: Centocor, Inc. | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2012-12-19